公开(公告)号：EP1586319B1

公开(公告)日：2009-10-21

申请号：EP05075779.8

申请日：2005-04-04

申请人： Noscira, S.A.

发明人： Martinez, Gil ,  Dorronsoro Diaz, Isabel ,  Alonso Cascon, Mercedes ,  Panizodel Pliego, Gema ,  Fuertes Huerta, Ana ,  Perez Puerto, Maria José ,  Medina Padilla, Miguel

IPC分类号： A61K31/433 ,  C07D285/08 ,  C07D417/04 ,  A61P25/28 ,  A61P3/10

CPC分类号： C07D285/08 ,  C07D417/04

公开(公告)号：EP2647634A1

公开(公告)日：2013-10-09

申请号：EP12382133.2

申请日：2012-04-02

申请人： NOSCIRA, S.A.

发明人： Medina Padilla, Miguel ,  Dominguez Correa, Juan Manuel ,  Fuertes Huerta, Ana ,  Palomo Nicolau, Francisco ,  Lopez Ogalla, Javier ,  Herrero Santos, Susana ,  Alonso Cascon, Mercedes ,  Alonso Gordillo, Diana ,  Rubio Arrieta, Laura

IPC分类号： C07D403/04 ,  A61K31/506 ,  A61P25/00 ,  A61P3/10

CPC分类号： C07D403/04

摘要： The present invention relates to new indole-pyrimidine derivatives of Formula (I), a process for obtaining them, a pharmaceutical composition comprising said compounds and their use in the treatment of several disease including cognitive, neurodegenerative or neurological diseases or conditions, diabetes, inflammatory and autoimmune diseases and cardiovascular disorders.

摘要翻译： 本发明涉及式（I）的新的吲哚 - 嘧啶衍生物，其获得方法，包含所述化合物的药物组合物及其在治疗包括认知，神经变性或神经疾病或病症，糖尿病，炎性 和自身免疫性疾病和心血管疾病。

公开(公告)号：EP1646622B1

公开(公告)日：2010-11-03

申请号：EP04743319.8

申请日：2004-07-09

申请人： NOSCIRA, S.A.

发明人： Martinez Gil, Ana ,  Dorronsoro Diaz, Isabel ,  Rubio Arrieta, Laura ,  Alonso Gordillo, Diana ,  Fuertes Huerta, Ana ,  Morales-Alcelay, Susana ,  Del Monte Millan, Maria ,  Garcia Palomero, Esther ,  Usan Egea, Paola ,  De Austria, Celia ,  Medina Padilla, Miguel ,  Munoz Ruiz, Pilar

IPC分类号： C07D401/12 ,  A61K31/473 ,  A61P25/28

CPC分类号： C07D401/12

摘要： The invention provides compounds of formula: (I) which have a tacrine moiety connected to an heterocyclic moiety through a linker. Through careful selection of the substituents and the linker, the activity and selectivity towards acetylcholinesterase can be modulated. The compounds show potent AChE inhibition activities together with modifications in the β-amyloid aggregation properties by binding simultaneously to the catalytic and peripheral AChE sites. They are useful in the treatment of AChE mediated diseases, such as the Alzheimer’s disease.